The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
National Institutes of Health · National Institute on Drug Abuse · +3 more institutions
Abstract
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD). Here, we examined the effects of semaglutide, a long-acting GLP-1 analogue, on biobehavioral correlates of alcohol use in rodents. A drinking-in-the-dark procedure was used to test the effects of semaglutide on binge-like drinking in male and female mice. We also tested the effects of semaglutide on binge-like and dependence-induced alcohol drinking in male and female rats, as well as acute effects of semaglutide on spontaneous inhibitory postsynaptic currents (sIPSCs) from central amygdala (CeA) and…
Citation impact
- FWCI
- 26.93
- Percentile
- 100%
- References
- 133
Authors
11- VCVicky Chuong
National Institutes of Health, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism
- MFMehdi Farokhnia
National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism
- SKSophia Khom
Scripps Research Institute, University of Vienna
- CPClaire Pince
National Institutes of Health, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism
- SKSophie K. Elvig
National Institutes of Health
Topics & keywords
- Semaglutide
- Alcohol use disorder
- Neurotransmission
- Endocrinology
- Alcohol
- Internal medicine
- Binge drinking
- Chemistry
- Good health and well-being